布鲁顿酪氨酸激酶
医学
多发性硬化
促炎细胞因子
酪氨酸激酶
表型
小胶质细胞
炎症
髓鞘
免疫学
癌症研究
药理学
受体
内科学
中枢神经系统
生物
生物化学
基因
标识
DOI:10.1016/j.ncl.2023.07.006
摘要
Multiple sclerosis (MS) can cause significant disability to patients via relapse-associated worsening and progression independent of relapses. The causes of neuronal and myelin damage can include lymphocyte-mediated inflammation and microglial activation. Bruton’s tyrosine kinase (BTK) is an enzyme that mediates B cell activation and the proinflammatory phenotype of microglia. Inhibiting BTK provides a novel therapeutic target for MS but also has a complicated pharmacology based on binding specificity, CNS penetration, half-life, and enzyme inhibition characteristics. Multiple agents are being studied in phase 3 trials, and each agent will have unique efficacy and safety profiles that must be considered individually.
科研通智能强力驱动
Strongly Powered by AbleSci AI